Longevity Tech Radar: FDA-Cleared AI, Biomarkers, and Preventive Diagnostics

The longevity clinic market is entering its dashboard era.

A few years ago, the sales pitch was simple: expensive supplements, IV drips, cryotherapy, maybe a biological-age test framed with the emotional subtlety of a tax audit. In 2026, the more serious end of the market is becoming much more diagnostic. Blood biomarkers, imaging, AI-assisted radiology, wearables, VO₂ estimates, genetic risk, and longitudinal dashboards are converging into one promise: we can see risk earlier, personalize more precisely, and intervene before disease becomes obvious.

That promise is partly real. It is also a wonderful place to hide overconfidence.

This week’s radar is a good example. Lucent Diagnostics announced a collaboration with Tempus to integrate blood-based Alzheimer’s biomarker testing into clinical workflows for neurologists.¹ FDA 510(k) decisions in late April added or updated tools relevant to the preventive-health stack, including AI mammography support, a new GE bone densitometry system, and radiology navigation software.²³⁴ A previously cleared wearable-derived VO₂peak module points toward a future where fitness biomarkers move from the sports lab into everyday clinical monitoring.⁵

For World Longevity Clinics readers, the important question is not “which technology sounds most futuristic?” It is: which technologies help a clinic make better decisions, and which merely make the brochure glow?

Quick answer: what changed this week?

Four signals matter for longevity clinics and buyers.

Signal	What happened	Why it matters	What is still unproven
Blood-based brain biomarkers enter workflows	Lucent Diagnostics and Tempus announced integration of LucentAD Complete into Tempus’ clinical ordering/care-gap platform	Cognitive-risk testing is moving from research labs into clinician workflows	Not a casual anti-aging screen; assay performance and patient selection matter
AI-assisted imaging keeps expanding	FDA records show late-April clearance for Lunit INSIGHT MMG v1.1.10, an AI mammography adjunct	Longevity clinics built around early detection will lean harder on AI radiology	Adjunctive AI is not a replacement for physician judgment or outcome proof
Body composition and bone-health tech keeps upgrading	FDA cleared GE’s Lunar Astra bone densitometer on April 20, 2026	DEXA remains one of the most actionable tests in longevity medicine	Better hardware does not automatically mean better programs
Wearable fitness biomarkers are moving toward medical use	Prolaio’s eVO₂peak module was FDA-cleared in late 2025 and links to a validation study of VO₂max estimation from biosignals	VO₂ max is becoming easier to track outside a lab	Estimated VO₂ is not the same as a full CPET, and it needs context

The meta-trend is clear: longevity tech is shifting from treatment theater to risk detection and decision support.

That is good news if clinics use it responsibly. It is less good if every new FDA-cleared device becomes a pretext for selling a five-figure “age reversal” program.

1. Blood-based Alzheimer’s biomarkers are getting closer to routine care

The freshest news is the Lucent Diagnostics/Tempus collaboration. Lucent Diagnostics, a Quanterix brand, said its LucentAD Complete multi-biomarker blood test will become available for neurologists to order through Tempus’ clinical ordering platform. Tempus will also build a care-gap program to identify patients who may benefit from guideline-directed Alzheimer’s biomarker testing.¹

That matters because brain aging is one of the areas where longevity clinics most want better early detection. The old pathway for Alzheimer’s pathology relied heavily on amyloid PET or cerebrospinal fluid testing. Those can be valuable, but they are expensive, invasive, limited by access, or all three. Blood-based biomarkers could make the diagnostic pathway less burdensome when used in the right patient population.

But the words “when used in the right patient population” are doing serious work.

A 2025 systematic review and meta-analysis in Alzheimer’s & Dementia evaluated blood-based biomarkers for detecting Alzheimer’s disease pathology in cognitively impaired individuals in specialized care settings. Across 49 observational studies, test performance varied widely: pooled sensitivity ranged from 49.3% to 91.4%, and pooled specificity from 61.5% to 96.7%, depending on analyte and assay platform. The authors emphasized that results should be interpreted in the context of the specific test, patient setting, and comprehensive clinical assessment.⁶

That is a very different message from: “Take this blood test at a wellness spa and find out if your brain is aging.”

For longevity clinics, the right use case is not broad fear-based screening. It is a cognitive-care pathway:

• symptoms, history, and cognitive assessment first;
• clear indication for biomarker testing;
• clinician interpretation;
• referral options;
• medication eligibility discussion where appropriate;
• follow-up rather than panic.

If a clinic offers brain biomarkers as one piece of a medical workup, that can be useful. If it presents them as a lifestyle curiosity next to NAD+ drips and a magnesium upsell, that is where the science starts quietly backing out of the room.

If cognitive risk is part of your decision process, start with the broader question in our guide to what a longevity health assessment should include, then ask whether the clinic has neurologist-level interpretation or referral pathways.

2. AI imaging is becoming infrastructure, not a novelty

The second signal is less flashy but important: AI imaging tools keep moving through the regulatory pipeline.

On April 23, 2026, FDA records show a substantially equivalent decision for Lunit INSIGHT MMG v1.1.10, a radiological computer-assisted detection/diagnosis software tool for lesions suspicious for breast cancer.² The 510(k) summary describes it as an AI-based adjunctive tool intended to aid detection, localization, and characterization of suspicious areas on mammograms; it is not intended to replace a complete physician review or clinical judgment.⁷

A separate April clearance for LungPoint Virtual Bronchoscopic Navigation Software is less directly “longevity” on the surface, but it points to the same infrastructure trend: more clinical navigation, quantification, and decision-support software around imaging-heavy care.⁴

That caveat is the whole story.

For diagnostic-first longevity clinics, AI radiology will become normal. Human Longevity Inc. already centers its model on deep diagnostics: full-body MRI, whole-genome sequencing, DEXA, VO₂ max, coronary calcium CT, biomarkers, and physician synthesis. Fountain Life markets an AI-guided diagnostic membership model. Biograph sits in the executive-physical category, with a long assessment day and physician-led interpretation. Prenuvo focuses on whole-body MRI and imaging-led early detection.

AI can help with this. It can support triage, flag suspicious findings, standardize reads, reduce missed lesions in certain contexts, and make high-volume imaging more scalable. But it does not remove the core tradeoff in preventive imaging: earlier detection versus incidental findings, follow-up cascades, anxiety, cost, and uneven evidence for broad screening.

That is why the best clinics will not say, “We use AI, therefore you are safer.” They will say:

• what the AI tool is cleared or validated to do;
• whether it is diagnostic, triage, quantification, or workflow support;
• who reviews the output;
• how false positives are handled;
• what follow-up pathway exists;
• whether the test is appropriate for your age, sex, risk, symptoms, and prior screening.

For a deeper version of that tradeoff, read our guide to full-body MRI at longevity clinics. The future is not “scan everyone, all the time.” The future is better selection, better interpretation, and fewer orphan findings.

3. DEXA remains boring, useful, and underrated

FDA records show GE’s Lunar Astra bone densitometer received a substantially equivalent decision on April 20, 2026.³ That may sound less exciting than AI mammography or blood biomarkers for Alzheimer’s disease.

Good. Some of the best longevity tools are not exciting.

DEXA sits in the sweet spot between medical usefulness and practical behavior change. Depending on protocol and software, it can measure bone mineral density, lean mass, fat mass, and sometimes visceral-fat estimates. Those are not abstract longevity vibes. They connect directly to fracture risk, sarcopenia risk, training plans, nutrition, menopause care, metabolic risk, and follow-up.

This is why strong clinics often include DEXA or body-composition testing in their diagnostic baseline. In the WLC database, examples include Progevita, Lanserhof, Human Longevity Inc., Fountain Life, Biograph, Prenuvo, and YEARS Berlin.

The practical question is not whether a clinic owns a shiny scanner. It is whether the result changes the plan.

A good DEXA-informed program should be able to answer:

• Is bone density normal, osteopenic, or osteoporotic?
• Is lean mass low for age, sex, height, and goals?
• Is visceral fat high enough to change metabolic priorities?
• Is there a training plan with progressive overload?
• Will the clinic retest at an interval that can actually show change?
• Who manages abnormal bone findings — the clinic, a primary doctor, or an endocrinologist?

DEXA is not glamorous. It is load-bearing. In a market addicted to molecular mystique, that almost makes it punk rock.

4. VO₂ max is becoming easier to estimate — but estimates need humility

Cardiorespiratory fitness is one of the most useful signals in longevity medicine. A measured VO₂ max or VO₂ peak reflects how well the cardiovascular, pulmonary, muscular, and metabolic systems cooperate under stress. It is not merely a fitness stat; it is a functional biomarker.

The problem is access. A gold-standard cardiopulmonary exercise test requires equipment, staff, safety protocols, and time. That is why many clinics use submaximal tests, treadmill protocols, bike tests, wearables, or estimates.

Prolaio’s eVO₂peak Module, cleared by FDA in December 2025 as an adjunctive cardiovascular status indicator, is a sign of where the field is going.⁵ The associated ClinicalTrials.gov record describes an ongoing observational study, still listed as recruiting in late 2025, designed to validate VO₂max and other CPET parameter estimates from biosignals, including motion from accelerometers and cardiopulmonary variables from ECG, collected during daily life.⁸

For longevity clinics, this matters because VO₂ max is moving from episodic testing toward continuous or semi-continuous monitoring.

That could be genuinely useful. It could help clinics track whether a patient’s program is improving functional capacity, not just lowering a methylation-clock number. It may also make fitness assessment more accessible to people who will never book a lab CPET.

But estimated VO₂ is not the same as measured CPET. It can be affected by device placement, algorithm assumptions, training status, medication, arrhythmias, illness, movement quality, and population fit. A useful clinic will treat estimated VO₂ as a trend or screening signal, then use full testing when it matters clinically.

If a longevity clinic sells “biological age” without measuring fitness, muscle, blood pressure, and metabolic risk, it is skipping the parts of aging that have handles.

5. NAD+ is moving into mainstream wellness channels — which raises the bar for evidence

One more signal from the recent radar: NAD+ products continue to move from niche longevity clinics into wider wellness distribution. Niagen Bioscience announced in March that OneSpaWorld would offer Niagen IV through Medi-Spa clinics on high-end cruise ships, with rollout across more than 80 onboard clinics.⁹

That story already earned its own WLC article because it captures a larger shift: longevity interventions are moving into travel, hospitality, and premium wellness channels. If a therapy can be sold at sea, it can be sold anywhere with a recliner and a consent form.

There is some science here. A 2026 retrospective tolerability pilot study compared commercially administered IV NAD+ and IV nicotinamide riboside (NR) in a real-world setting. Participants received four consecutive days of 500 mg NAD+ IV or NR IV. NR infusions averaged 37 minutes versus 97 minutes for NAD+ IV, with fewer moderate-to-severe infusion symptoms in the NR group; safety markers were generally stable over 30 days, while exploratory metabolic outcomes were variable and warrant further study.¹⁰

That is not nothing. It is also not proof of age reversal.

The proper conclusion is restrained: NAD+ and NR delivery formats are improving, tolerability may differ, and commercial channels are expanding. Human outcome evidence for broad longevity claims remains limited. If you are evaluating clinics offering NAD+ therapy, use our NAD+ therapy guide and the cruise-ship analysis of Niagen IV and OneSpaWorld before assuming that a shorter infusion equals a longer life.

What this means for the longevity clinic buyer

The clinic market is splitting into three broad categories.

1. Data-rich medical programs

These clinics lead with diagnostics, physician interpretation, and follow-up. They may include imaging, genomics, DEXA, cardiometabolic testing, VO₂ max, cognitive assessment, blood biomarkers, and longitudinal tracking. The best versions are expensive but coherent.

Examples include Human Longevity Inc., Fountain Life, Biograph, Princeton Longevity Center, and some European programs that combine diagnostics with residential behavior change.

If you are comparing this category, start with Fountain Life vs Human Longevity Inc. and then use the clinic comparison tool.

2. Imaging-led early detection programs

These focus heavily on MRI, CT, DEXA, or organ-specific imaging. They can be useful for specific buyers, especially those seeking a deep baseline or targeted screening. But imaging-led programs need clear policies for incidental findings and follow-up.

Prenuvo is the clearest example of an imaging-centered model. It may be useful, but it is not the same thing as a complete longevity clinic unless combined with physician review, cardiometabolic care, behavior-change support, and referrals.

3. Treatment-led wellness clinics

These lead with IVs, peptides, hormones, cryotherapy, exosomes, stem cells, red light, ozone, or similar interventions. Some include useful diagnostics; others use diagnostics mainly as sales scaffolding.

The buyer rule is simple: testing should narrow treatment, not decorate treatment.

If every abnormality leads to the same menu of drips, peptides, and supplements, the clinic is not practicing precision medicine. It is practicing precision invoicing.

The questions to ask before buying a tech-heavy program

Use this checklist before paying for a diagnostic-heavy longevity assessment.

1. Which tests are clinically validated, and which are exploratory? FDA clearance, CE marking, CLIA lab status, and peer-reviewed validation are not interchangeable.

2. What happens if the result is abnormal? A finding without a pathway can become anxiety with a PDF attached.

3. Who interprets the data? Physician, radiologist, neurologist, genetic counselor, exercise physiologist, health coach, algorithm — these are different roles.

4. How are false positives handled? Especially for broad imaging, cancer screening, brain biomarkers, and multi-omics.

5. Will the clinic coordinate referrals? Early detection is only valuable if the next step is competent.

6. What would change if the test were normal? If the answer is “nothing,” the test may be more curiosity than care.

7. Are interventions tied to indications? NAD+, peptides, hormones, plasmapheresis, or stem cells should not be automatic responses to vague “accelerated aging” language.

8. Is there follow-up measurement? Longevity medicine without longitudinal tracking is just a very expensive snapshot.

For the broader buyer framework, use our evidence-based checklist for choosing a longevity clinic, the 2026 rankings, or Find Your Clinic if you want a guided shortlist.

Practical takeaway: buy interpretation, not technology

The useful future of longevity clinics is not one more dashboard. It is a better clinical loop:

1. measure risk;
2. interpret it correctly;
3. act on what is actionable;
4. avoid treating noise;
5. remeasure at the right interval;
6. escalate to specialists when needed.

The technologies in this week’s radar — blood-based Alzheimer’s biomarkers, AI imaging, upgraded DEXA, estimated VO₂, and better NAD+ delivery — all fit somewhere inside that loop. None of them replace it.

A serious clinic will tell you where the evidence is strong, where it is early, and where marketing is outrunning medicine. That is the standard to look for.

Because in longevity medicine, the most valuable device in the room is still not the scanner, the assay, or the algorithm.

It is the clinician who knows when not to overreact.

Sources

Footnotes

1. Lucent Diagnostics/Quanterix and Tempus announcement via Morningstar/Business Wire, May 6, 2026: Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer’s Biomarker Testing into Clinical Workflows. ↩ ↩²

2. FDA 510(k) Premarket Notification K260320: Lunit INSIGHT MMG (v1.1.10), decision date April 23, 2026. ↩ ↩²

3. FDA 510(k) Premarket Notification K252718: Lunar Astra, decision date April 20, 2026. ↩ ↩²

4. FDA 510(k) Premarket Notification K260009: LungPoint Virtual Bronchoscopic Navigation Software, decision date April 24, 2026. ↩ ↩²

5. FDA 510(k) Premarket Notification K252204: prolaio eVO₂peak Module, decision date December 16, 2025. ↩ ↩²

6. Pahlke S, et al. 2025. Blood-based biomarkers for detecting Alzheimer’s disease pathology in cognitively impaired individuals within specialized care settings: a systematic review and meta-analysis. Alzheimer’s & Dementia. ↩

7. FDA 510(k) summary PDF for K260320: Lunit INSIGHT MMG v1.1.10. ↩

8. ClinicalTrials.gov NCT05678530: Observational, Non-Interventional Study Supporting Validation of VO2Max Estimation Methods Using Results in Patients Receiving Standard of Care Cardiopulmonary Exercise Tests. ↩

9. Niagen Bioscience/OneSpaWorld announcement via Morningstar/Business Wire, March 31, 2026: Niagen IV launches across Medi-Spa clinics on high-end cruise ships. ↩

10. Reyna K, et al. 2026. Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Frontiers in Aging. ↩